DUBLIN, July 13, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Big Pharma Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.
Global Big Pharma Partnering Terms and Agreements 2010 to 2016 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Big Pharma agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
Key benefits
- In-depth understanding of Big Pharma deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Big Pharma agreements with real life case studies
- Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
- Identify most active Big Pharma dealmakers since 2010
- Insight into terms included in a Big Pharma partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
In Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Big Pharma dealmaking
Chapter 3 - Leading Big Pharma deals
Chapter 4 - Most active Big Pharma dealmakers
Chapter 5 - Big Pharma contracts dealmaking directory
Chapter 6 - Big Pharma dealmaking by technology type
Chapter 7 - Partnering resource center
For more information visit http://www.researchandmarkets.com/research/wc3gd4/global_big_pharma
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
